Cannabis firm to pay $4 million for stake in Vancouver biotech

CannaRoyalty Corp. to acquire 20% stake in Anandia Laboratories
Anandia Labs co-founder Jonathan Page agreed to sell 20% of his company to CannaRoyalty because he likes CannaRoyalty's expertise in extraction and post-processing | Chung Chow

With the federal government on the verge of legalizing marijuana, high-value strategic assets in the cannabis sector are becoming valuable.

That is how Ottawa-based cannabis firm CannaRoyalty Corp. explained its interest in buying a 20% stake in Vancouver’s Anandia Laboratories.

The companies announced January 9 that they have signed a letter of intent for CannaRoyalty (CSE:CRZ) to acquire that 20% stake in Anandia for $4 million.

Anandia is a biotechnology company that tests medical marijuana and uses genomics for plant breeding. It has completed extensive research into cannabis genetics and has built a significant intellectual-property position that includes cannabinoid pathway patents, according to the company.

Anandia also been issued a dealers licence from Health Canada pursuant to the provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations.

This dealers licence allows Anandia to analyze and extract cannabis, and cultivate cannabis for breeding and strain improvement. This licensing gives Anandia the ability to do research and development, and develop products that would not otherwise be permitted for licensed

producers under Health Canada’s Access to Cannabis for Medical Purposes Regulations.

Because pesticide use is a concern in any product consumed by humans, Anandia also plans to use genomics to develop pest-resistant strains.

“We have elected to partner with CannaRoyalty given their expertise in extraction, post-processing and the development of proprietary formulations,” said Anandia co-founder Jonathan Page.

CannaRoyalty is a fully integrated, active investor and operator in the legal cannabis sector. It intends to build and support a diversified portfolio of assets that it thinks will grow in value as marijuana legalization becomes reality in Canada.

Some of these assets are research, consumer brands, devices and intellectual property.

Genome BC last fall announced that it had invested $500,000 in Anandia.

gkorstrom@biv.com 

@GlenKorstrom 

comments powered by Disqus

More from Technology

‘Tribal warfare’ hurts med-tech sector: hub founder

Infighting over limited capital harms everyone, says Innovation Boulevard player

Read Article

Infographic: Do insiders or outsiders pose a bigger cybersecurity threat?

Which is worse: a cybersecurity threat that originates from within a business, or one coming from outside? What are the typical costs associated with both ...

Read Article

Pop your trunk: Amazon has a delivery

B.C. company developing technology with Amazon to deliver packages to drivers’ vehicles

Read Article

Tyler Orton: Vancouver tech could benefit from Trump

Read Article

Upstart Vancouver eyes Toronto’s fintech crown

Financial technology firms find talent, interest on the wane in capital-rich T.O.  

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×